Transcription factors and atrial fibrillation

Cardiovascular Research

Volumn 101, Issue 2, 2014, Pages 194-202

  Mahida, Saagar ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Atrial fibrillation; Transcription factors arrhythmias

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR PITX2; TRANSCRIPTION FACTOR PRRX1; TRANSCRIPTION FACTOR TBX5; TRANSCRIPTION FACTOR ZFHX3; UNCLASSIFIED DRUG;

DISEASE PREDISPOSITION; GENE MUTATION; GENETIC ASSOCIATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ATRIAL FIBRILLATION; TRANSCRIPTION FACTORS ARRHYTHMIAS;

ANIMALS; ATRIAL FIBRILLATION; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HEART CONDUCTION SYSTEM; HUMANS; MUTATION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 84893028239     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt261     Document Type: Review

References (129)

1. Lloyd-Jones DM,Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004;110: 1042-1046
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114: 119-125
3. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008;92:17-40, ix.
4. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28:316-321
5. PrehnAW, Topol B, Stewart S, Glaser SL, O'Connor L,WestDW. Differences in treatment patterns for localized breast carcinoma among Asian/Pacific islander women. Cancer 2002;95:2268-2275
6. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP,Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003;107:2920-2925
7. KrahnAD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.AmJ Med 1995;98:476-484
8. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ,Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The FraminghamHeart Study. JAMA 1994;271:840-844
9. KrahnAD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.AmJ Med 1995;98:476-484
10. Fox CS, Parise H, D'Agostino RB Sr, Lloyd-Jones DM, Vasan RS,Wang TJ et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004;291: 2851-2855
11. Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. Hum Genet 2005;118:179-184
12. Arnar DO, Thorvaldsson S, Manolio TA, Thorgeirsson G, Kristjansson K, Hakonarson H et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006;27:708-712
13. Øyen N, Ranthe MF, Carstensen L, Boyd HA, Olesen MS, Olesen SP et al. Familial aggregation of lone atrial fibrillation in young persons. J AmColl Cardiol 2012;60:917-921
14. Mahida S, Lubitz SA, Rienstra M, Milan DJ, Ellinor PT. Monogenic atrial fibrillation as pathophysiological paradigms. Cardiovasc Res 2011;89:692-700
15. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012;44:670-675
16. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK et al. Common variants inKCNN3are associated with lone atrial fibrillation. Nat Genet 2010;42:240-244
17. Benjamin EJ, Rice KM, Arking DE, Pfeufer A, van Noord C, Smith AV et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet 2009;41:879-881
18. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007; 448:353-357
19. Latchman DS. Transcription factors: An overview. Int J Biochem Cell Biol 1997;29: 1305-1312
20. Martinez E. Multi-protein complexes in eukaryotic gene transcription. Plant Mol Biol 2002;50:925-947
21. Online Mendelian Inheritance in Man, OMIMw. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). Available at: Http://omim.org / 2013 (accessed) .
22. Clark KL, Yutzey KE, Benson DW. Transcription factors and congenital heart defects. Annu Rev Physiol 2006;68:97-121
23. Nattel S, Burstein B, DobrevD. Atrial remodeling and atrial fibrillation: Mechanisms and implications. Circ Arrhythm Electrophysiol 2008;1:62-73
24. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 2011;121:2955-2968
25. Olesen MS, NielsenMW, Haunsø S, Svendsen JH. Atrial fibrillation: The role ofcommon and rare genetic variants. Eur J Hum Genet 2013; Jul 10. doi: 10.1038/ejhg.2013.139.[Epub ahead of print].
26. Darbar D, Roden DM. Genetic mechanisms of atrial fibrillation: Impact on response to treatment. Nat Rev Cardiol 2013;10:317-329
27. Postma AV, van de Meerakker JB, Mathijssen IB, Barnett P, Christoffels VM, Ilgun A et al. Again-of-functionTBX5mutation is associated with atypical Holt-Oramsyndromeand paroxysmal atrial fibrillation. Circ Res 2008;102:1433-1442
28. YangYQ,WangMY, Zhang XL, TanHW, ShiHF, JiangWFet al.GATA4loss-of-function mutations in familial atrial fibrillation. Clin Chim Acta 2011;412:1825-1830
29. Jiang JQ, Shen FF, FangWY, Liu X, Yang YQ. NovelGATA4 mutations in lone atrial fibrillation. Int J Mol Med 2011;28:1025-1032
30. Wang J, Sun YM, Yang YQ. Mutation spectrum of theGATA4 gene in patients with idiopathic atrial fibrillation. Mol Biol Rep 2012;39:8127-8135
31. PoschMG,Boldt LH, Polotzki M, Richter S, Rolf S, PerrotAet al. Mutations in the cardiac transcription factorGATA4 in patients with lone atrial fibrillation. Eur J Med Genet 2010; 53:201-203
32. Gu JY,Xu JH, Yu H, YangYQ. NovelGATA5 loss-of-function mutations underlie familial atrial fibrillation. Clinics (Sao Paulo) 2012;67:1393-1399
33. Wang XH, Huang CX, Wang Q, Li RG, Xu YJ, Liu X et al. A novel GATA5 loss-of-function mutation underlies lone atrial fibrillation. Int J Mol Med 2013;31:43-50
34. Yang YQ,Wang J,Wang XH,Wang Q, TanHW, ZhangMet al. Mutational spectrum of the GATA5 gene associated with familial atrial fibrillation. Int J Cardiol 2012;157: 305-307
35. WeiD, Bao H, LiuXY, Zhou N,Wang Q, LiRGet al.GATA5 loss-of-function mutations underlie Tetralogy of Fallot. Int J Med Sci 2013;10:34-42
36. YangYQ, Li L,Wang J, Zhang XL, Li RG, XuYJ et al.GATA6 loss-of-function mutation in atrial fibrillation. Eur J Med Genet 2012;55:520-526
37. Yang YQ,Wang XH, TanHW, Jiang WF, FangWY, Liu X. Prevalence and spectrum of GATA6 mutations associated with familial atrial fibrillation. Int J Cardiol 2012;155: 494-496
38. Gutierrez-Roelens I, De Roy L, Ovaert C, Sluysmans T, Devriendt K, BrunnerHG et al. A novel CSX/NKX2-5 mutation causes autosomal-dominant AV block: Are atrial fibrillation and syncopes part of the phenotype? Eur J Hum Genet 2006;14:1313-1316
39. Ritchie MD, Rowan S, Kucera G, Stubblefield T, Blair M, Carter S et al. Chromosome 4q25 variants are genetic modifiers of rare ion channelmutations associated with familial atrial fibrillation. J Am Coll Cardiol 2012;60:1173-1181
40. MullerCW, Herrmann BG. Crystallographic structure of the T domain-DNA complex of the Brachyury transcription factor. Nature 1997;389:884-888
41. McCulley DJ, Black BL. Transcription factor pathways and congenital heart disease. Curr Top Dev Biol 2012;100:253-277
42. Basson CT, Bachinsky DR, Lin RC, Levi T, Elkins JA, Soults J et al. Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat Genet 1997;15:30-35
43. Li QY, Newbury-Ecob RA, Terrett JA, Wilson DI, Curtis AR, Yi CH et al. Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. Nat Genet 1997;15:21-29
44. Lehner R,GoharkhayN, Tringler B, Fasching C, Hengstschlager M. Pedigree analysis and descriptive investigation of three classic phenotypes associated with Holt-Oram syndrome. J Reprod Med 2003;48:153-159
45. Mott BH, Bassman J, Pikaart MJ. A molecular dissection of the interaction between the transcription factor Gata-1 zinc finger and DNA. Biochem Biophys Res Commun 2004; 316:910-917
46. Laverriere AC, MacNeill C, Mueller C, Poelmann RE, Burch JB, Evans T. GATA-4/5/6, a subfamily of three transcription factors transcribed in developing heart and gut. J Biol Chem 1994;269:23177-23184
47. Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CAet al.GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 2003;424:443-447
48. Tomita-Mitchell A, Maslen CL, Morris CD, Garg V, Goldmuntz E. GATA4 sequence variants in patients with congenital heart disease. J Med Genet 2007;44:779-783
49. Kodo K, Nishizawa T, Furutani M, Arai S, Yamamura E, Joo K et al. GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling. Proc Natl Acad Sci USA 2009;106:13933-13938
50. HuangRT,Xue S,XuYJ, Yang YQ. Somatic mutations in theGATA6 gene underlie sporadic tetralogy of Fallot. Int J Mol Med 2013;31:51-58
51. Lin X, Huo Z, Liu X, Zhang Y, Li L, Zhao H et al. A novel GATA6 mutation in patients with tetralogy of Fallot or atrial septal defect. J Hum Genet 2010;55:662-667
52. Li J, Liu WD, Yang ZL, Yang YQ. Novel GATA6 loss-of-function mutation responsible for familial atrial fibrillation. Int J Mol Med 2012;30:783-790
53. Gehring WJ, Affolter M, Burglin T. Homeodomain proteins. Annu Rev Biochem 1994;63: 487-526
54. Benson DW, Silberbach GM, Kavanaugh-McHugh A, Cottrill C, Zhang Y, Riggs S et al. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest 1999;104:1567-1573
55. McElhinney DB, Geiger E, Blinder J, Benson DW, Goldmuntz E. NKX2.5 mutations in patients with congenital heart disease. J Am Coll Cardiol 2003;42:1650-1655
56. Boldt LH, PoschMG,Perrot A, Polotzki M, Rolf S, ParwaniASet al. Mutational analysis of the PITX2 and NKX2-5 genes in patients with idiopathic atrial fibrillation. Int J Cardiol 2010;145:316-317
57. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010;363:166-176
58. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007; 448:353-357
59. Sinner MF, Ellinor PT, Meitinger T, Benjamin EJ, Kaab S. Genome-wide association studies of atrial fibrillation: Past, present, and future. Cardiovasc Res 2011;89:701-709
60. Kaab S, Darbar D, van Noord C, Dupuis J, Pfeufer A, Newton-Cheh C et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J 2009;30:813-819
61. Logan M, Pagan-Westphal SM, Smith DM, Paganessi L, Tabin CJ. The transcription factor Pitx2 mediates situs-specific morphogenesis in response to left-right asymmetric signals. Cell 1998;94:307-317
62. Mommersteeg MT, Hoogaars WM, PrallOW, de Gier-de Vries C, Wiese C, Clout DE et al. Molecular pathway for the localized formation of the sinoatrial node. Circ Res 2007; 100:354-362
63. Kitamura K, Miura H, Miyagawa-Tomita S, Yanazawa M, Katoh-Fukui Y, Suzuki R et al. Mouse Pitx2 deficiency leads to anomalies of the ventral body wall, heart, extra- and periocular mesoderm and right pulmonary isomerism. Development 1999;126: 5749-5758
64. Lin CR, Kioussi C, O'Connell S, Briata P, Szeto D, Liu F et al. Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis. Nature 1999;401: 279-282
65. Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, Scheld HH et al. PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. Circ Cardiovasc Genet 2011;4:123-133
66. Wang J, Klysik E, Sood S, Johnson RL,Wehrens XH, Martin JF. Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc Natl Acad Sci USA 107:9753-9758
67. Chinchilla A, Daimi H, Lozano-Velasco E, Dominguez JN, Caballero R, Delpon E et al. PITX2 insufficiency leads to atrial electrical and structural remodeling linked to arrhythmogenesis. Circ Cardiovasc Genet 2011;4:269-279
68. Li C,Wang F, Yang Y, Fu F, Xu C, Shi L et al. Significant association of SNP rs2106261 in theZFHX3 gene with atrial fibrillation in a Chinese Han GeneID population.HumGenet 2011;129:239-246
69. Berry FB, Miura Y, Mihara K, Kaspar P, Sakata N, Hashimoto-Tamaoki T et al. Positive and negative regulation of myogenic differentiation of C2C12 cells by isoforms of the multiple homeodomain zinc finger transcription factor ATBF1. J Biol Chem 2001;276: 25057-25065
70. Jung CG, Kim HJ, KawaguchiM, Khanna KK, Hida H, AsaiKet al. Homeotic factorATBF1 induces the cell cycle arrest associated with neuronal differentiation. Development 2005;132:5137-5145
71. Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB et al. Frequent somatic mutations of the transcription factorATBF1 in human prostate cancer. Nat Genet 2005;37:407-412
72. Bergwerff M, Gittenberger-de Groot AC, DeRuiter MC, van Iperen L, Meijlink F, Poelmann RE. Patterns of paired-related homeobox genes PRX1 and PRX2 suggest involvement in matrix modulation in the developing chick vascular system. Dev Dyn 1998; 213:59-70
73. Bergwerff M, Gittenberger-de GrootAC, Wisse LJ, DeRuiter MC,Wessels A, Martin JF et al. Loss of function of the Prx1 and Prx2 homeobox genes alters architecture of the great elastic arteries and ductus arteriosus. Virchows Arch 2000;436:12-19
74. Ihida-Stansbury K, McKean DM, Gebb SA, Martin JF, Stevens T, Nemenoff R et al. Paired-related homeobox gene Prx1 is required for pulmonary vascular development. Circ Res 2004;94:1507-1514
75. Hardy J, Singleton A. Genomewide association studies and human disease. NEngl J Med 2009;360:1759-1768
76. Freedman ML, Monteiro AN, Gayther SA, Coetzee GA, Risch A, PlassCet al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 2011;43: 513-518
77. Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, Almendro V et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci USA 2010;107:9742-9746
78. Wasserman NF, Aneas I, Nobrega MA. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res 2010;20:1191-1197
79. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, HeintzmanNet al. 9p21DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature 2011;470:264-268
80. Chung MK, Barnard J, Hanna P, Hsu J, Tchou M, Wirka RC et al. Regulation of genes in human atria nearSNPs associated with atrial fibrillation andPRinterval. Circulation 2011; 124:A8221
81. Christ T, Boknik P,Wohrl S,Wettwer E, Graf EM, Bosch RF et al. L-type Ca2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation 2004;110:2651-2657
82. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002;54:230-246
83. Nattel S, Shiroshita-Takeshita A, Brundel BJ, Rivard L. Mechanisms of atrial fibrillation: Lessons from animal models. Prog Cardiovasc Dis 2005;48:9-28
84. Chen CL, Lin JL, Lai LP, Pan CH, Huang SK, Lin CS. Altered expression of FHL1, CARP, TSC-22 and P311 provide insights into complex transcriptional regulation in pacing-induced atrial fibrillation. Biochim Biophys Acta 2007;1772:317-329
85. Shang LL, Sanyal S, Pfahnl AE, Jiao Z, Allen J, LiuHet al. NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am J Physiol Cell Physiol 2008;294:C372-C379
86. He X, Gao X, Peng L,Wang S, Zhu Y, Ma H et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ Res 2011;108:164-175
87. Hunyady L, Catt KJ. PleiotropicAT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006;20:953-970
88. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995;375: 247-250
89. Goette A, Lendeckel U, Klein HU. Signal transduction systems and atrial fibrillation. Cardiovasc Res 2002;54:247-258
90. Koinuma D, Shinozaki M, Komuro A, Goto K, Saitoh M, HanyuAet al. Arkadia amplifies TGF-beta superfamily signalling through degradation of Smad7. EMBO J 2003;22: 6458-6470
91. Kim YH, Lim DS, Lee JH, Shim WJ, Ro YM, Park GH et al. Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp Mol Med 2003;35:336-349
92. Charital YM, van Haasteren G, Massiha A, SchlegelW, Fujita T. A functional NF-kappaB enhancer element in the first intron contributes to the control of c-fos transcription. Gene 2009;430:116-122
93. Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy 2004;3:361-375
94. Yue L, Melnyk P, Gaspo R,Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999;84:776-784
95. Qi XY, Yeh YH, Xiao L, Burstein B, Maguy A, Chartier D et al. Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. Circ Res 2008;103: 845-854
96. Natale A, Raviele A, Arentz T, Calkins H, Chen SA, Haissaguerre M et al. Venice chart international consensus document on atrial fibrillation ablation. J Cardiovasc Electrophysiol 2007;18:560-580
97. Aldhoon B, Melenovsky V, Peichl P, Kautzner J. New insights into mechanisms of atrial fibrillation. Physiol Res 2010;59:1-12
98. MommersteegMT, Brown NA, PrallOW, de Gier-de Vries C, Harvey RP, Moorman AF et al. Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium. Circ Res 2007;101:902-909
99. Khan R. Identifying and understanding the role of pulmonary vein activity in atrial fibrillation. Cardiovasc Res 2004;64:387-394
100. Hocini M,HoSY,KawaraT, LinnenbankAC, Potse M, ShahDet al. Electrical conduction in canine pulmonary veins: Electrophysiological and anatomic correlation. Circulation 2002;105:2442-2448
101. Christoffels VM, Mommersteeg MT, Trowe MO, Prall OW, de Gier-de Vries C, Soufan AT et al. Formation of the venous pole of the heart from an Nkx2-5-negative precursor population requires Tbx18. Circ Res 2006;98:1555-1563
102. Ravens U, Cerbai E. Role of potassium currents in cardiac arrhythmias. Europace 2008; 10:1133-1137
103. Xia M, Jin Q, Bendahhou S, He Y, LarroqueMM, Chen Y et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun 2005;332: 1012-1019
104. Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, ShaoQet al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 2006;354:2677-2688
105. Yang YQ, Liu X, Zhang XL,Wang XH, Tan HW, Shi HF et al. Novel connexin40 missense mutations in patients with familial atrial fibrillation. Europace 2010;12: 1421-1427
106. Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 2008;359:158-165
107. Verheule S, Sato T, Everett Tt, Engle SK, Otten D, Rubart-von der Lohe M et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004;94:1458-1465
108. Seidman JG, Seidman C. Transcription factor haploinsufficiency: When half a loaf is not enough. J Clin Invest 2002;109:451-455
109. Inoue K, Khajavi M, Ohyama T, Hirabayashi S, Wilson J, Reggin JD et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet 2004;36:361-369
110. Bruneau BG. The developmental genetics of congenital heart disease. Nature 2008;451: 943-948
111. Takeuchi JK, Lou X, Alexander JM, Sugizaki H, Delgado-Olguin P, Holloway AK et al. Chromatin remodelling complex dosage modulates transcription factor function in heart development. Nat Commun 2011;2:187
112. Birchler JA, Veitia RA. The gene balance hypothesis: From classical genetics to modern genomics. Plant Cell 2007;19:395-402
113. Biben C,Weber R, Kesteven S, Stanley E, McDonald L, Elliott DA et al. Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. Circ Res 2000;87:888-895
114. Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, Caron S et al. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 2001;106:709-721
115. Allison LA. Chapter 11: Transcription in Eukaryotes. Fundamental Molecular Biology. Oxford: John Wiley & Sons, 2012. p. 312
116. Johnston JJ, Olivos-Glander I, Killoran C, Elson E, Turner JT, Peters KF et al. Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: Robust phenotype prediction from the type and position of GLI3 mutations. Am J Hum Genet 2005;76:609-622
117. Grill C, Bergsteinsdottir K, OgmundsdottirMH,PogenbergV, Schepsky A, WilmannsM et al. MITF mutations associated with pigment deficiency syndromes and melanoma have different effects on protein function. Hum Mol Genet 2013
118. FlakerGC,Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527-532
119. Kumar K, Zimetbaum PJ. New and emerging antiarrhythmic drugs for atrial fibrillation: What may become available to the clinician in the near future. Curr Treat Options Cardiovasc Med 2009;11:373-380
120. Skibsbye L, Diness JG, Sorensen US, Hansen RS, Grunnet M. The duration of pacing-induced atrial fibrillation is reduced in vivo by inhibition of small conductance Ca(2+)-activated K(+) channels. J Cardiovasc Pharmacol 2011;57:672-681
121. Brennan P, Donev R, Hewamana S. Targeting transcription factors for therapeutic benefit. Mol Biosyst 2008;4:909-919
122. Karamouzis MV, Papavassiliou AG. Transcription factor networks as targets for therapeutic intervention of cancer: The breast cancer paradigm. Mol Med 2011;17: 1133-1136
123. LiuY, Ludes-Meyers J,ZhangY,Munoz-Medellin D,KimHT, LuCet al. Inhibitionof AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002;21:7680-7689
124. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010; 363:1397-1409
125. YazawaM, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011; 471:230-234
126. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225-229
127. Kooperberg C, LeBlanc M, Obenchain V. Risk prediction using genome-wide association studies. Genet Epidemiol 2010;34:643-652
128. Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res 2007;17:1520-1528
129. Dermitzakis ET, Stranger BE. Genetic variation in human gene expression. Mamm Genome 2006;17:503-508